Dr. Lal Path Labs · NSE: LALPATHLAB · BSE: 539524
Q2 FY20 results · Jul–Sep 2019
Dr. Lal Path Labs reported revenue from operations of ₹365.60 crore (up 15.1% from Q2 FY19) and net profit of ₹81.00 crore (up 41.1% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 365.60 | 317.50 | +15.1% | 335.20 | +9.1% |
| Other income | 14.80 | 10.90 | +35.8% | 14.40 | +2.8% |
| Total income | 380.40 | 328.40 | +15.8% | 349.60 | +8.8% |
| Profit before tax | 102.30 | 88.10 | +16.1% | 89.40 | +14.4% |
| Net profit for the period | 81.00 | 57.40 | +41.1% | 59.10 | +37.1% |
| Attributable to shareholders of the company | 80.50 | 57.00 | +41.2% | 58.80 | +36.9% |
| EPS, basic (₹) | 9.77 | 6.92 | +41.2% | 7.14 | +36.8% |
| Net margin (%) | 22.2 | 18.1 | 17.6 |
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 351.20 | 307.20 | +14.3% | 324.50 | +8.2% |
| Other income | 16.20 | 10.70 | +51.4% | 14.10 | +14.9% |
| Total income | 367.40 | 317.90 | +15.6% | 338.60 | +8.5% |
| Profit before tax | 99.80 | 84.80 | +17.7% | 86.70 | +15.1% |
| Net profit for the period | 79.50 | 55.20 | +44.0% | 57.30 | +38.7% |
| EPS, basic (₹) | 9.65 | 6.71 | +43.8% | 6.95 | +38.8% |
| Net margin (%) | 22.6 | 18.0 | 17.7 |
Consolidated
- Filed with BSE
- 08 Nov 2019, 17:38 IST
- Board meeting
- 08 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Nov 2019, 17:38 IST
- Board meeting
- 08 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE